留置针改良穿刺法在痉挛肢体静脉穿刺中的应用

注册号:

Registration number:

ChiCTR2600127129 

最近更新日期:

Date of Last Refreshed on:

2026-06-25 11:15:41 

注册时间:

Date of Registration:

2026-06-25 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

留置针改良穿刺法在痉挛肢体静脉穿刺中的应用

Public title:

Application of indwelling needle modified puncture method in venipuncture of spastic limbs in patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

留置针改良穿刺法在颈脊髓损伤患者痉挛肢体静脉穿刺中的应用

Scientific title:

Application of indwelling needle modified puncture method in venipuncture of spastic limbs in patients with spinal cord injury

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

宋杰 

研究负责人:

宋杰 

Applicant:

Song Jie 

Study leader:

Song Jie 

申请注册联系人电话:

Applicant telephone:

+86 10 8756 7548

研究负责人电话:

Study leader's
telephone:

+86 10 8756 7548

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

871941102@qq.com

研究负责人电子邮件:

Study leader's E-mail:

871941102@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市丰台区角门北路11号院4-603

研究负责人通讯地址:

北京市丰台区角门北路10号

Applicant address:

Room 603, Building 4, No.11 Jiaomen North Road, Fengtai District, Beijing

Study leader's address:

No. 10, Jiaomen North Road, Fengtai District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国康复研究中心

Applicant's institution:

China Rehabilitation Research Center

研究负责人所在单位:

北京博爱医院

Affiliation of the Leader:

Beijing Bo'ai Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026-016-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国康复研究中心医学伦理委员会科研与医疗新技术新项目伦理组

Name of the ethic committee:

Medical Ethics Committee of China Rehabilitation Research Center

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-06 00:00:00

伦理委员会联系人:

何照楠

Contact Name of the ethic committee:

He Zhaonan

伦理委员会联系地址:

北京市丰台区角门北路10号

Contact Address of the ethic committee:

No. 10, Jiaomen North Road, Fengtai District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 87020512

伦理委员会联系人邮箱:

Contact email of the ethic committee:

hznhzk@163.com

研究实施负责(组长)单位:

北京博爱医院

Primary sponsor:

Beijing Bo'ai Hospital

研究实施负责(组长)单位地址:

北京市丰台区角门北路10号

Primary sponsor's address:

No. 10, Jiaomen North Road, Fengtai District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京博爱医院

具体地址:

北京市丰台区角门北路10号

Institution
hospital:

Beijing Bo'ai Hospital

Address:

No. 10, Jiaomen North Road, Fengtai District, Beijing

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

self funded

研究疾病:

无  

Target disease:

None

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

验证一种留置针改良穿刺法在颈脊髓损伤患者痉挛肢体静脉穿刺中的效果应用,为护士外周静脉穿刺工作提供实践经验。  

Objectives of Study:

To verify the clinical application effect of an improved indwelling needle puncture method in venous puncture for spastic limbs of patients with cervical spinal cord injury, and to provide practical experience for nurses in peripheral venous puncture.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.已置入其他输液装置者;
2.患者皮肤有感染、破损、水肿、严重疤痕等不适于留置针输液治疗者;
3.患者认知障碍或意识不清等原因不能配合者;
4.肢体彩超检查示穿刺肢体有静脉血栓者;
5.合并凝血功能严重障碍(如INI>1.5或血小板<50×10⁹/L);
6.输注药液属于化疗药或高渗药物等高危药品者;
7.预估输液时长不足3天者;
8.参与其他可能干扰本研究结果的临床试验。

Exclusion criteria:

1. Patients who have already had other infusion devices implanted; 2. Patients with skin infections, damage, edema, severe scars or other conditions that are not suitable for indwelling needle infusion therapy; 3. Patients who cannot cooperate due to cognitive impairment, disturbance of consciousness or other reasons; 4. Patients with venous thrombosis in the punctured limb shown by limb color Doppler ultrasound examination; 5. Complicated with severe coagulation disorders (e.g., INR > 1.5 or platelets < 50×10⁹/L); 6. Patients whose infused drugs are high-risk drugs such as chemotherapeutic drugs or hypertonic drugs; 7. Patients whose estimated infusion duration is less than 3 days; 8. Patients participating in other clinical trials that may interfere with the results of this study.

研究实施时间:

Study execute time:

From 2026-06-30 00:00:00 To 2026-12-10 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-30 00:00:00 To 2026-10-30 00:00:00

干预措施:

Interventions:

组别:

A组(实验组)

样本量:

40

Group:

Group A (Experimental Group)

Sample size:

干预措施:

留置针改良穿刺法

干预措施代码:

Intervention:

Improved puncture method for indwelling needles

Intervention code:

组别:

B组(对照组)

样本量:

40

Group:

Group B (Control Group)

Sample size:

干预措施:

留置针传统穿刺法(北京市静脉穿刺标准操作规程)

干预措施代码:

Intervention:

Improved puncture method for indwelling needles

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京博爱医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Bo'ai Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

穿刺点红肿发生率

指标类型:

次要指标

Outcome:

Incidence of redness and swelling at the puncture site

Type:

Secondary indicator

测量时间点:

留置针留置期间均需要观察

测量方法:

留置针留置期间观察穿刺点是否有红肿现象,记录发生次数,并计算发生率。

Measure time point of outcome:

During indwelling of the needle,

Measure method:

During indwelling of the needle, observe the puncture site for redness and swelling, record the number of occurrences, and calculate the incidence rate.

指标中文名:

穿刺点出血发生率

指标类型:

次要指标

Outcome:

Incidence of bleeding at the puncture site

Type:

Secondary indicator

测量时间点:

留置针留置期间均需要观察

测量方法:

留置针留置期间观察穿刺点是否有出血现象,记录发生次数,并计算发生率。

Measure time point of outcome:

During indwelling of the needle,

Measure method:

During indwelling of the needle, observe the puncture site for bleeding, record the number of occurrences, and calculate the incidence rate.

指标中文名:

自然留置时长

指标类型:

次要指标

Outcome:

Natural indwelling duration

Type:

Secondary indicator

测量时间点:

留置针因为堵塞或穿刺点发生红肿、渗液而需要拔除时

测量方法:

留置针穿刺时间点至拔除时间点的实际时长

Measure time point of outcome:

When an indwelling needle needs to be removed due to blockage, or redness, swelling and exudation at

Measure method:

The actual duration from the time of indwelling needle insertion to removal.

指标中文名:

首次穿刺成功率

指标类型:

主要指标

Outcome:

First-Attempt puncture success rate

Type:

Primary indicator

测量时间点:

留置针穿刺完成后15分钟

测量方法:

穿刺中见回血,穿刺后可顺利输入液体,并维持输液通畅至少15分钟,穿刺点无肿胀渗液。

Measure time point of outcome:

15 minutes after completion of indwelling needle puncture

Measure method:

Blood return was observed during puncture; after puncture, fluid could be infused smoothly, and unobstructed infusion was maintained for at least 15 minutes, with no swelling or exudation at the puncture site.

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不参与实施操作的专人使用随机数字表发产生随机数列,分成2组

Randomization Procedure (please state who generates the random number sequence and by what method):

A dedicated person not involved in the implementation of the operation generates a random number sequence using a random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

开放标签,对评估者设盲

Blinding:

Open-label study with blinded-evaluators

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No sharing of raw dat

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

制作EXCEL表格,评估者收集患者一般资料、疾病信息、科研数据,对资料保密,科研团队成员以外的人员不可接触。不使用EDC。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

An Excel spreadsheet will be created for assessors to collect patients' general information, disease-related data and research data. All data shall be kept confidential and shall not be accessible to anyone outside the research team.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-06-25 11:15:10